PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology. SON-1010, Sonnet's lead proprietary monofunct.
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics, Inc : Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) will post its quarterly earnings results on Monday, February 12th. Sonnet BioTherapeutics Stock Up 2.7 % NASDAQ SONN opened at $1.51 on Friday. Sonnet BioTherapeutics has a one year low of $1.08 and a one year high of $26.40. The business has a 50 day simple moving average […]